

Vaccines and Global Health: The Week in Review 26 October 2024 :: Issue 772 Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to

David R. Curry, MS

Editor and

Executive Director Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click <u>here</u> to donate and thank you in advance for your contribution.

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers
- :: Think Tanks

Milestones, Perspectives

::::::

::::::

Polio - PHEIC

Polio this week as of 23 October 2024 - GPEI

Headlines

- :: **24 October 2024 marks World Polio Day**, a chance for stakeholders of the Global Polio Eradication Initiative (GPEI) to raise awareness and resources of the urgent need to eradicate this disease once and for all. Rotary International and Rotarians around the world are once again at the forefront of this global campaign, bringing together the public and civil society in promoting the cause of polio eradication. More at the World Polio Day <u>'Take Action'</u> page.
- :: Newest Polio Gender Champion announced: Rt Hon Anneliese Dodds MP, Minister for Development at the Foreign, Commonwealth and Development Office and Minister for Women and Equalities at the Department for Education, United Kingdom. <u>More</u>.
- :: Gaza outbreak response: while the second round of the Gaza outbreak response was implemented in key areas, in northern Gaza the activity has been postponed amid escalating conflict and impeded access. More.

Summary of new polioviruses this week, cases and positive environmental isolates:

- Afghanistan: one wild poliovirus type 1 (WPV1) case and 10 WPV1-positive environmental samples
- Pakistan: seven WPV1 cases and one WPV1-positive environmental sample
- Chad: three circulating vaccine-derived poliovirus type 2 (cVDPV2) cases and two cVDPV2-positive environmental samples
- Djibouti: one cVDPV2-positive environmental sample
- Niger: once cVDPV2 case and one cVDPV2-positive environmental sample
- Nigeria: five cVDPV2 cases

::::::

<u>Intense bombardments, mass displacements and lack of access in northern Gaza force the postponement of polio vaccination campaign</u>

Joint press release from UNICEF and WHO

EAST JERUSALEM/AMMAN/GENEVA, 23 October 2024 - Due to the escalating violence, intense bombardment, mass displacement orders, and lack of assured humanitarian pauses across most of northern Gaza, the Polio Technical Committee for Gaza, including the Palestinian Ministry of Health, World Health Organization (WHO), United Nations Children's Fund (UNICEF), the United Nations Relief and Works Agency for Palestine Refugees (UNRWA) and partners have been compelled to postpone the third phase of the polio vaccination campaign, which was set to begin today. This final phase of the ongoing campaign aimed to vaccinate 119,279 children across northern Gaza.

The current conditions, including ongoing attacks on civilian infrastructure, continue to jeopardize people's safety and movement in northern Gaza, making it impossible for families to safely bring their children for vaccination, and for health workers to operate.

All logistics, supplies and trained human resources were prepared to vaccinate children across northern Gaza with a second dose of novel oral polio vaccine type 2 (nOPV2), following a first-round conducted across the Gaza Strip from 1-12 September 2024.

However, given that the area currently approved for temporary humanitarian pauses was substantially reduced—now limited only to Gaza City, a significant decrease from the first round—many children in northern Gaza would have missed out on the polio vaccine dose...

::::::

occupied Palestinian territory

Gaza Polio Campaign October 2024

- Download day 1 updates
- Download day 2 updates
- Download day 3 updates
- Download day 4 updates
- Download day 5 updates

Polio this week in occupied Palestinian territory

- No cVDPV2-positive environmental samples were reported this week.
- No cVDPV2 cases were reported this week. The total number of cases from Gaza this year remains one.

::::::

85 per cent of children affected by polio in 2023 lived in fragile and conflict-affected countries

On World Polio Day, UNICEF warns that polio cases in these settings have more than doubled over the past five years

NEW YORK, 24 October 2024 — Of the 541 children affected by polio globally in 2023, 85 per cent live in the 31 fragile, conflict-affected, and vulnerable countries, according to a new UNICEF analysis on World Polio Day.

Polio cases in these settings have more than doubled in the past five years, while routine childhood immunization has dropped from 75 to 70 per cent – well below the 95 per cent needed for community immunity.

The data issue a stark warning that the life-threatening disease continues to thrive in areas where life is most precarious, and where conflict, natural disasters, humanitarian crises, other destabilizing factors make it difficult to deliver critical healthcare.

"In conflict, children face more than bombs and bullets; they are at risk of deadly diseases that should no longer exist," said UNICEF Executive Director Catherine Russell. "In many countries, we are witnessing the collapse of healthcare systems, destruction of water and sanitation infrastructure, and the displacement of families, triggering a resurgence of diseases like polio. Children are being left paralyzed, unable to walk, play, or attend school."

A global decline in childhood immunization has also led to an increase in polio outbreaks, including in countries that had been polio-free for decades. Nowhere is this more evident than in conflict-affected areas, with 15 out of 21 such countries – including Afghanistan, Democratic Republic of Congo, Somalia, South Sudan, and Yemen – currently battling polio...

Successful polio vaccination campaigns in fragile, conflict-affected, and vulnerable countries are critical to stopping further cases and protecting children who are already

vulnerable. Humanitarian pauses are essential to ensure healthcare workers can reach children and deliver vaccines safely.

The battle against polio is hardest in the most challenging places, but eradication is within reach. UNICEF, which delivers over 1 billion doses of polio vaccines annually – the largest share of its global vaccine deliveries – urges governments, partners, and donors to:

- Prioritize vaccination of all children against polio, especially in conflict and humanitarian settings and in countries with low immunization coverage across Africa and parts of Asia.
- Strengthen immunization systems to ensure all children receive essential, lifesaving vaccines.
- Protect humanitarian and healthcare workers delivering vaccines, and respect essential humanitarian pauses needed for campaign success.
- Provide critical resources to the Global Polio Eradication Initiative and Gavi, the Vaccine Alliance, to quickly halt outbreaks and ensure children are vaccinated.
- Elevate polio eradication on political agendas at all levels, prioritizing innovative solutions and coordinated actions to enhance immunization campaign quality.

"The spread of polio not only puts children in affected countries at immediate risk but also poses a growing threat to neighbouring countries," added Russell. "The final push is the hardest, but now is the time to act. We cannot rest until every child, in every corner of the world, is safe from polio – once and for all."

::::::

Africa – Pharmaceuticals and Vaccines

The AfCFTA and the procurement of pharmaceuticals and vaccines

ODI Research Teport

21 October 2024 :: 41 pages Derrick Abudu, Yohannes Ayele

PDF: https://odi.org/documents/9286/ODI Report -

_The_AfCFTA_and_the_procurement_of_pharmaceuticals_and_vaccines.pdf

Access to affordable, essential medicines is crucial for public health, yet remains a significant challenge across Africa. High prices, driven by fragmented procurement and limited local manufacturing, hinder healthcare systems. The African Continental Free Trade Area (AfCFTA) presents a unique opportunity to transform the pharmaceutical sector in Africa and address these issues.

This report examines the role of the AfCFTA in facilitating the procurement of essential pharmaceuticals and vaccines in Africa. It **analyses the impact of the AfCFTA's rules of origin (RoOs) on the cost of imported medicines and vaccines**, and explores how the landmark agreement can be used to support the development and growth of local pharmaceutical manufacturing capacity and value chains.

Key findings

- The AfCFTA has the potential to significantly drive down the cost of medicines and vaccines in Africa through pooled procurement and local production.
- While rules of origin for pharmaceutical products are moderately restrictive, the preferential tariff benefits for firms meeting these rules are minimal.
- Eliminating the rules of origin requirement for pharmaceutical and vaccine products could further simplify procurement.

- Reducing tariffs and non-tariff barriers on imported critical pharmaceutical components like active pharmaceutical ingredients (APIs) will foster the cost-competitiveness of local manufacturers and promote regional production.
- Capacity-building measures are needed to improve the technical capacity of procurement bodies and border management authorities.

::::::

The World Medical Association General Assembly 2024 in summary

23.10.2024

...In addition to the revised Declaration of Helsinki, other declarations, resolutions and statements adopted by the WMA General Assembly included:

WMA Statement on Epidemics and Pandemics

Adopted by the 68th General Assembly, Chicago, October 2017 and revised by the 75th WMA General Assembly, Helsinki, Finland, October 2024 [Excerpt; Editor's text bolding] PREAMBLE

History demonstrates that new diseases will emerge, and old diseases re-emerge unpredictably and pose significant threats to global health.

Epidemics and pandemics highlight deep-rooted inequalities, hitting less-resourced regions hardest due to their constrained resources, fragile health systems, and significant disease burdens. **The common but differentiated responsibilities (CBDR) principle can be applied to pandemic prevention**, preparedness and response (PPPR) in order to bring equity and justice in cooperation between states.

The accelerating pace of epidemic-prone diseases, compounded by the repercussions of geopolitical conflicts, environmental degradation, climate change, increased human encroachment into natural ecosystems, antimicrobial resistance, widening socio-economic disparities, global travel, and the intrinsic link between the health of humans, animals, and our shared environment, underscores the vulnerability of global health security.

Integrating the One Health approach acknowledges the critical interdependence of all living organisms and their habitats, essential for understanding the emergence and spread of diseases and highlighting the need for a multisectoral, interdisciplinary and evidence-based approach to global health threats.

Robust and effective global surveillance is pivotal for improving the prevention and response to infectious diseases, enabling earlier detection and identification of emergent threats. The rapid spread of epidemics and pandemics in regions with underfunded and underdeveloped public health infrastructures highlights the **urgent need for a global cooperative framework**. Such a framework must prioritise the development of resilient health systems capable of withstanding the challenges posed by infectious diseases, thereby safeguarding the health and well-being of populations worldwide.

An investment in strengthening public health, primary care and other aspects of health systems is crucial for enhancing the capacity to prevent, detect, contain, and manage disease outbreaks, laying a solid foundation for core public health functions essential.

Particular attention should be paid to individuals in fragile, conflict-affected, and vulnerable settings; additionally other individual vulnerabilities factors should also be addressed including but not limited to disability, age, gender, indigeneity, ethnicity, etc... [Recommendations follow...]

::::::

WMA Statement on Human Papillomavirus Vaccination

Adopted by the 68th General Assembly, Chicago, October 2017 and revised by the 75th WMA General Assembly, Helsinki, Finland, October 2024 [Excerpt; Editor's text bolding]

PREAMBLE

Human papillomavirus (HPV) vaccination presents a unique and valuable opportunity for physicians to substantially prevent morbidity and mortality from certain cancers in all populations, and to improve maternal health. This may result in economic benefits for countries who achieve widespread HPV vaccination in their population in the current move towards preventive and promotive healthcare. The HPV vaccine therefore merits consideration by the World Medical Association (WMA) separately from other vaccines.

HPV is, for the most part, sexually transmitted virus and is so common that most sexually active adults become infected at some point in their lives. Most infections are asymptomatic and resolve without medical intervention. However, **HPV** is the cause of nearly 100% of cervical cancer cases. Thirteen of the 40 types of HPV are oncogenic and, when they cause a persistent infection can produce cervical cancer as well as cancer of the vagina, vulva, anus, penis, the head and neck, oropharynx and anogenital area.

Few diseases reflect global inequities as much as cancer of the cervix. It is the fourth most common cancer in females globally, and most cervical cancer cases and deaths are in low and middle-income countries.

HPV vaccines protect against infections caused by targeted HPV types. All available vaccines afford protection against types 16 and 18, which are the most oncogenic types and can also offer protection against anogenital warts. HPV vaccination is recommended for females and males from 9-45 years of age and the immunocompromised people. HPV vaccines are safe, effective, and well tolerated.

WHO recommends a one or two-dose schedule HPV vaccination for females between 9-14 and 15-20 years old. Females older than 21 years require two doses with a 6-month interval. Benefits of vaccinating young males include protection against genital warts and cancer in addition to preventing transmission of HPV to sexual partners.

In 2020 the World Health Assembly adopted the <u>Global Strategy for cervical cancer elimination</u>. To achieve accelerated elimination of cervical cancer, by 2030, 90% of girls will be fully vaccinated with the HPV vaccine by the age of 15, screening programs using a high-performance test will be running to screen 70% of women by the age of 35 and again by the age of 45 and 90% of women with invasive cancer will be managed.

School-based vaccination or systematic community programs are strategies that will increase vaccine accessibility to the appropriate age groups, particularly targeting youths prior to the commencement of sexual activity to ensure maximum benefit.

- 1. Reaffirming its <u>Statement on Access of Women and Children to Healthcare</u> and its <u>Statement on the Prioritisation of Immunisation</u>, the WMA insists on the rights of all women, children, and indeed all people to adequate, safe medical care and urges governments to commit resources to immunisation programs.
- 2. The WMA encourages expedited development and funding of programs to make safe, high quality HPV vaccines widely available to both females and males.
- 3. The WMA strongly advocates for the provision of reliable, fast, and accessible cervical cancer screening programs for the detection and treatment of precancerous lesions in all countries, especially in those that have high mortality rates from cervical cancer.
- 4. WMA clearly points out that HPV vaccination should not replace cervical cancer screening programs...

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

WHO & Regional Offices [to 26 Oct 2024]

https://www.who.int/news Selected News/Announcements/Statements 23 October 2024 News release

<u>Intense bombardments, mass displacements and lack of access in northern Gaza force the postponement of polio vaccination campaign</u>

22 October 2024 Statement

<u>Patients transferred, critical supplies denied as high-risk, on WHO-led joint mission in northern Gaza amid intense hostilities</u>

21 October 2024 News release

WHO global network expands digital health certification for Hajj pilgrims

The World Health Organization (WHO) and the Kingdom of Saudi Arabia announced a new milestone digital health collaboration today to expand the Hajj health card initiative to support the roughly 3 million pilgrims who undertake the holy pilgrimage every year.

The Hajj health card, built on the WHO Global Digital Health Certification Network's public key infrastructure, summarizes critical health information, such as medication needs, allergies, immunization status and pre-existing conditions. The card gives individuals agency over their own health information when they travel to Saudi Arabia so that they can provide authorized health providers access to accurate, up-to-date patient summary information and obtain personalized quality care...

::::::

WHO Regional Offices

Selected Press Releases, Announcements

WHO African Region

:: 25 October 2024

Chad introduces malaria vaccine in triple-vaccine rollout for children

:: 23 October 2024

Working with communities to curb mpox spread in the Democratic Republic of the Congo

:: 23 October 2024

Kenya, Uganda cross-border polio vaccination reaches 6.5 million children

:: 23 October 2024

Enhancing polio detection with advanced sequencing technology

WHO Region of the Americas PAHO

:: 24 Oct 2024

New Pandemic Fund grants to help bolster pandemic preparedness and response for countries of the Americas

PAHO to support countries in the implementation of critical resources to fund disease surveillance, early warning systems and other key projects in ten countries of the RegionWashington D.C. 23 October 2024 (PAHO) - As part of its second round of funding, released on 18 October 2024, the Pandemic Fund (PF) has approved five new projects for Latin... 24 Oct 2024

<u>PAHO hosts Economic and Health Dialogue of the Americas to strengthen health systems</u> and economic resilience in the region

Washington, D.C., October 24, 2024 (PAHO)— The Pan American Health Organization (PAHO) today convened the Economic and Health Dialogue of the Americas (EHA), bringing together leaders from the health and finance sectors to address the challenges faced by countries in the post-pandemic era. "The recent COVID-19 pandemic has shown us how...
23 Oct 2024

PAHO celebrates 30 years without wild polio in the Americas

Washington, D.C., October 23, 2024 (PAHO) – On World Polio Day (October 24), the Pan American Health Organization (PAHO) is celebrating the 30th anniversary of the certification of the eradication of wild poliovirus transmission in the Region of the Americas.In 1975, the region reported nearly 6,000 cases of polio. However, thanks to child...

WHO South-East Asia Region SEARO

:: World Polio Day

24 October 2024 Statement by Saima Wazed, WHO Regional Director for South-East Asia
Today, on World Polio Day, established by Rotary International, I extend my heartfelt congratulations
to all the countries and partners in the WHO South-East Asia Region for achieving and maintaining a
decade of polio-free status. The world observes World Polio Day on 24th October, the birth date of
Jonas Salk, who led the first team to develop a vaccine against poliomyelitis...

WHO European Region EURO

:: 24 October 2024 News release

Polio-free status retained, but European Region must increase vigilance

WHO Eastern Mediterranean Region EMRO

:: <u>Yemen battling variant poliovirus outbreak amid humanitarian crisis</u> 24 October 2024

:: <u>Somalia renews its commitment to end polio and ensure vaccination for every child</u> 24 October 2024

:: WHO intensifies efforts to combat TB, HIV, and Leishmaniasis control in Syria 24 October 2024

WHO Western Pacific Region

:: 24 October 2024 Media release

Regional health leaders agree to improve financing to achieve universal health coverage, p...

:: 23 October 2024 Media release

Ten additional countries in the Western Pacific Region pledge to invest in WHO

::::::

WHO - Emergency situation reports

Latest WHO official reports for emergency situations. Latest WHO official reports for emergency situations.

Multi-country outbreak of mpox, External situation report #41- 26 October 2024

Overview

This is the 41st situation report for the multi-country outbreak of mpox, which provides details on the latest epidemiological trends, including an the global mpox epidemiological situation, as of 30 September 2024 and the epidemiological situation for mpox in Africa (including countries in the WHO African Region and some countries in the WHO Eastern Mediterranean Region), with data as of 20 October 2024.

The report also includes a special focus on the description of the mpox literature repository and the summary of the latest WHO interim guidance for mpox in school settings.

::::::

Disease Outbreak News (DONs)

Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

25 October 2024 | Marburg virus disease - Rwanda

::::::

Weekly Epidemiological Record

https://www.who.int/publications/journals/weekly-epidemiological-record

Vol. 99, No. 42, pp. 591-608 18 October 2024

PDF: https://iris.who.int/bitstream/handle/10665/379277/WER9942-eng-fre.pdf

- :: Recommended composition of influenza virus vaccines for use in the 2025 southern hemisphere influenza season
- :: Genetic and antigenic characteristics of zoonotic influenza A viruses and development of candidate vaccine viruses for pandemic preparedness

::::::

New WHO Publications

https://www.who.int/publications/i

Selected

25 October 2024

Eliminating HIV, viral hepatitis, sexually transmitted infections and tuberculosis as public health problems...

23 October 2024

Considerations for border health and points of entry for mpox: interim guidance

Overview

On 14 August 2024, the Director-General of the World Health Organization determined that the upsurge of mpox in a growing number of countries in Africa constitutes a new public health emergency of international concern (PHEIC) under the International Health Regulations (IHR) (2005).

Health authorities should strengthen public health surveillance, risk communication, community engagement and emergency coordination efforts as well as disease prevention and clinical care related to mpox at and around relevant points of entry (PoEs), in close coordination with all governmental and non-State actors working at and around PoEs. Persons with suspected or confirmed mpox and any individuals showing signs and symptoms compatible with mpox should refrain from non-essential travel and close contact with others.

This interim guidance provides advice to support the implementation of the standing and temporary recommendations related to border health, international travel and PoEs issued by the Director-General in line with the required capacities and provisions of the IHR (2005).

22 October 2024

Regional consultation on Draft Global Strategy for Traditional Medicine 2025:2034 and to set the research...

22 October 2024

<u>Interim medical countermeasures network regional entities: meeting report, Geneva, Switzerland, 12–13...</u>

... At the request of Member States, WHO is collaborating with partners to assess the readiness of the MCM ecosystem for responding to pandemic influenza, novel coronavirus, and pathogen X (a hypothetical, unknown pathogen). The aim of the meeting was to identify gaps and suggest actionable steps to address them. Initial analyses show a need for enhanced capacities across the MCM value chain, such as fast-tracked research and development (R&D), scalable manufacturing, end-to-end health emergency supply chains, integrated delivery, and financing. Recognizing the importance of regional capacities, the meeting provided updates on <u>i-MCM-Net</u> activities, discussed preliminary findings and gaps emerging from the i-MCM-Net mapping report (<u>Defining access to countermeasures: Landscape report, executive summary</u>), engaged regional stakeholders in a collaborative discussion about challenges, and foster cross-regional dialogues. As part of this meeting, regional entities reflected on their mandates, initiatives, and collaborations related to the end-to-end MCM value chain...

::::::

USA – HHS, FDA, CDC

HHS

News

<u>USDA/HHS Fact Sheet: Biden-Harris Administration Takes New Action to Halt the Spread of Bird Flu, including in California and Washington</u>

October 24, 2024 News Release

FDA

Press Announcements

FDA Roundup: October 25, 2024

:: On Wednesday, the FDA published a Consumer Update, <u>FDA's Critical Role in Ensuring Safe and Effective Flu Vaccines</u>, reminding the public that the flu vaccine received at a doctor's office or pharmacy is the result of year-round work of highly skilled microbiologists, epidemiologists, physicians and other public health experts. As new strains of flu viruses emerge, the FDA closely coordinates with

sister agencies and works with manufacturers to help the development of vaccines to protect from the flu. All FDA-approved flu vaccines are safe and effective.

:: On Tuesday, the FDA approved the vaccine Abrysvo for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV. Since 2023, Abrysvo has been approved for the prevention of LRTD caused by RSV in individuals 60 years of age and older and for use in pregnant individuals at 32 through 36 weeks gestational age for the prevention of LRTD and severe LRTD caused by RSV in infants from birth through six months of age. Abrysvo is manufactured by Pfizer Inc.

FDA VRBPAC

Advisory Committee Calendar

<u>Vaccines and Related Biological Products Advisory Committee December 12, 2024 Meeting</u> Announcement - 12/12/2024

CDC/ACIP [U.S.] [to 26 Oct 2024]

http://www.cdc.gov/media/index.html

Latest News

<u>CDC Recommends Lowering the Age for Pneumococcal Vaccination from 65 to 50 Years</u> <u>Old</u>

Today, CDC Director Mandy Cohen endorsed the CDC Advisory Committee on Immunization Practices' (ACIP) recommendation for lowering the age for pneumococcal vaccination from 65 to 50 years old.Oct 23, 2024

<u>CDC Recommends Second Dose of 2024-2025 COVID-19 Vaccine for People 65 Years and Older and for People Who are Moderately or Severely Immunocompromised</u>

- Today, CDC Director Mandy Cohen endorsed the CDC Advisory Committee on Immunization Practices' (ACIP) recommendation for people 65 years and older and those who are moderately or severely immunocompromised...Oct 23, 2024

ACIP Meetings

Next ACIP Meeting February 26-27, 2025

MMWR Weekly

https://www.cdc.gov/mmwr/index2024.html

October 24, 2024 / No. 42

PDF of this issue

- <u>Genomic Surveillance for SARS-CoV-2 Variants: Circulation of Omicron XBB and JN.1 Lineages United States, May 2023—September 2024</u>
- <u>Locally Acquired (Autochthonous) Mosquito-Transmitted Plasmodium vivax Malaria Saline</u> County, Arkansas, September 2023
- Notes from the Field: First Locally Acquired Dengue Virus Infections Pasadena, California, October—December 2023

		:	
	i	i	

Europe

European Medicines Agency [EMA]

https://www.ema.europa.eu/en/news

News & Press Releases

Fostering regulatory collaboration to improve access to mpox medicines

Global regulators discuss available knowledge supporting mpox medicine development and approval 25 October 2024

European Centre for Disease Prevention and Control

https://www.ecdc.europa.eu/en

News/Updates/Reports/Publications [Selected]

Confirmed mpox clade Ib case in Germany, risk remains low for EU/EEA

23 Oct 2024

Surveillance and monitoring

Communicable disease threats report, 19-25 October 2024, week 43

25 Oct 2024

This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 19-25 October 2024 and includes updates on avian influenza A(H5N1), Marburg virus disease, Mpox, dengue, West Nile virus infections, cholera and an overview of respiratory virus epidemiology in the EU/EEA.

::::::

Africa CDC [to 26 Oct 2024]

https://africacdc.org/

Press Releases, Statements [Selected] No new digest content identified.

::::::

China CDC

http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [to 26 Oct 2024]

http://en.nhc.gov.cn/

News

No new digest content identified.

National Medical Products Administration – PRC [to 26 Oct 2024]

http://english.nmpa.gov.cn/

News

No new digest content identified.

China CDC

CCDC Weekly Reports: Current Volume (6)

2024-10-25 / No. 43 COPD ISSUE

PDF of this issue

 Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, August 2024*

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

Organization Announcements

Paul G. Allen Frontiers Group [to 26 Oct 2024]

https://alleninstitute.org/news-press/

News

No new digest content identified.

BMGF - Gates Foundation [to 26 Oct 2024]

https://www.gatesfoundation.org/ideas/media-center

Press Releases & Statements

No new digest content identified.

Bill & Melinda Gates Medical Research Institute [to 26 Oct 2024]

https://www.gatesmri.org/news

The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people News: Articles and Publications

No new digest content identified.

CARB-X [to 26 Oct 2024]

https://carb-x.org/

News

No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations [to 26 Oct 2024]

http://cepi.net/

CEPI News

No new digest content identified.

CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES [to 26]

Oct 2024]

https://cioms.ch/

News; Publications; Events No new digest content identified.

DARPA - Defense Advanced Research Projects Agency [U.S.] [to 26 Oct 2024

https://www.darpa.mil/news

News

No new digest content identified.

Duke Global Health Innovation Center [to 26 Oct 2024]

https://dukeghic.org/

News

<u>Tracking and Analyzing Medical Countermeasures for Emerging Health Challenges: Mpox</u> October 25, 2024

The COVID-19 pandemic exposed significant global inequities in the access to therapeutics, vaccines, testing, and other medical interventions that could limit the range and impact of the disease. These global inequities are not limited to the COVID-19 pandemic and need to be critically addressed in the ongoing mpox outbreak. Through Quickstart, we aim to serve as an external, independent source for tracking actions to meet commitments, catalyzing additional commitments to meet the need, and holding the world to account for the mpox response.

EDCTP [to 26 Oct 2024]

http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials

Νρινο

No new digest content identified

Emory Vaccine Center [to 26 Oct 2024]

http://www.vaccines.emory.edu/ Vaccine Center News No new digest content identified.

European Vaccine Initiative [to 26 Oct 2024]

http://www.euvaccine.eu/ Latest News, Events No new digest content identified.

Evidence Aid [to 26 Oct 2024]

Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.

http://www.evidenceaid.org/

It is with great sadness that we announce the closure of Evidence Aid as a charity on 31 October 2024. This difficult decision had to be taken despite best efforts, due to insufficient funds to continue the operation of the charity and a lack of prospects for further funding.

Fondation Merieux [to 26 Oct 2024]

http://www.fondation-merieux.org/

News, Events No new digest content identified.

Gavi [to 26 Oct 2024] https://www.gavi.org/ Press Releases 25 October 2024

Chad launches vaccination against malaria, pneumococcal disease and rotavirus diarrhea

24 October 2024

The Interim Government of Bangladesh launches the final phase of the HPV vaccination campaign, targeting over 6.2 million girls, to achieve nationwide coverage

GE2P2 Global Foundation [to 26 Oct 2024]

www.ge2p2.org

News/Analysis/Publications-Digests/Statements

- :: Vaccines and Global Health: The Week in Review Current edition
- :: Informed Consent: A Monthly Review October 2024
- :: Public Consultations Watch :: Global Calls for Input/Public Comment 16 Oct 2024 Issue 24

GHIT Fund [to 26 Oct 2024]

https://www.ghitfund.org/newsroom/press

Press Releases

No new digest content identified.

Global Fund [to 26 Oct 2024]

https://www.theglobalfund.org/en/news/

News Releases

No new digest content identified.

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 26 Oct 2024]

https://www.glopid-r.org/news/

News

23/10/2024

Pandemic PACT's Outbreak Tracker

In response to new or re-emerging outbreaks, the Pandemic PACT team has developed <u>real-time</u> <u>tracking and analysis of outbreak research data</u> by collating existing data from their database and intensifying their collection efforts.

Hilleman Laboratories [to 26 Oct 2024]

http://www.hilleman-labs.org/

News & Insights

No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 26 Oct 2024]

https://www.hhmi.org/news

Press Room

No new digest content identified.

Human Immunome Project [nee Human Vaccines Project] [to 26 Oct 2024]

https://www.humanimmunomeproject.org/

News

No new digest content identified.

IAVI [to 26 Oct 2024] https://www.iavi.org/News, Features

Features

IAVI at the World Vaccine Congress Europe

October 23, 2024

IAVI leaders will chair sessions and share the latest on our emerging infectious diseases program, vaccine innovation, and more at Europe's largest vaccine conference.

INSERM [to 26 Oct 2024]

https://www.inserm.fr/en/home/

Press Releases

Global Reach: Inserm Celebrates in Washington, DC, 60 Years of Research and Innovation 25 Oct 2024 |

In celebration of its 60th anniversary, Inserm is emphasizing its scientific collaboration with the United States and Canada. This privileged and fruitful relationship with North America will be highlighted during a day of scientific and institutional exchanges on October 29, 2024, at the French Embassy in Washington, DC. The event will be attended by Professor Didier Samuel, President and CEO of Inserm, along with representatives from numerous partner institutions. The agenda will include the initiation of new collaborations with leading American scientific institutions, the presentation of the 2024 Inserm International Award to a distinguished researcher, the strengthening of Inserm's presence in Washington, DC, and the launch of the Inserm Abroad Network.

International Coalition of Medicines Regulatory Authorities [ICMRA]

http://www.icmra.info/drupal/en/news Selected Statements, Press Releases, Research 25 October 2024

Fostering regulatory collaboration to improve access to mpox medicines

Global regulators discuss available knowledge supporting mpox medicine development and approval International regulators have published a report highlighting their considerations on the development, clinical trials and availability of vaccines and therapeutics for mpox. The report presents the outcomes of a workshop that was organised by EMA under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA).

Meeting participants discussed the current epidemiological status and the availability of mpox vaccines in African countries. Other topics discussed included efforts to fill the evidence gap regarding the use of vaccines in children and pregnant women, the need to establish effective surveillance systems, and the best regulatory pathways for approval of new vaccines and treatments. International regulators stressed the need for large clinical trials, which are most likely to generate the evidence

required to enable faster development and rapid approval of mpox medicines. They also agreed that using a more coordinated approach would be the most effective strategy to tackle current and future public health emergencies...

ICH [International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use] [to 26 Oct 2024]

https://www.ich.org/ News/Pubs/Press Releases [Selective] No new digest content identified.

ICRC [to 26 Oct 2024]
https://www.icrc.org/en/whats-new
What's New [Selected]
No new digest content identified.

IFFIm

http://www.iffim.org/ Press Releases/Announcements

<u>IFFIm returns to market with US\$ 1 billion 3-year bond to support global vaccine</u> programs

23 Oct 2024

- Funds will support Gavi's immunisation initiatives and CEPI's vaccine research
- Bond is backed by contributions from 11 sovereign donors
- Sania Nishtar, Gavi CEO: "Today's bond issue provides us with vital flexibility in our mission to protect millions of children from preventable diseases and to protect our world from the threat of future pandemics."

Polio: a VaccinesWork guide

24 Oct 2024

This week, Gavi's VaccinesWork shines its spotlight on polio, a disease the world is on the verge of vanquishing.

IFRC [to 26 Oct 2024]
http://media.ifrc.org/ifrc/news/press-releases/
Press Releases [Selected]
No new digest content identified.

Institut Pasteur [to 26 Oct 2024] https://www.pasteur.fr/en/press-area Press Documents Press Info 23.10.2024

Pasteur Network members Unite Global Efforts to Accelerate mRNA Vaccine Research

PNAM2024: Pasteur Network members Unite Global Efforts to Accelerate mRNA Vaccine Research through Strategic Memorandum...

ISC / International Science Council [to 26 Oct 2024]

https://council.science/current/

ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.

Latest Updates

blog 24 October 2024

<u>Transforming science organizations: The impact of women's leadership on institutional</u> reform

Mónica Moraes, a biologist specialized in palm trees, is a full-time professor, and researcher at the Herbario Nacional and Instituto de Ecología of the Universidad Mayor de San Andrés in Bolivia. From 2021 until mid-2024, she was the first woman President of the Bolivian Academy of Sciences. Breaking the culture of silence, she championed change, advocating for women's representation and redefining institutional practices.

International Union of Immunological Societies (IUIS)

https://iuis.org/

News/Events [Selected]

IUIS 2025: Empower the Next Generation of Scientists!

October 10, 2024

We need your help to bring 500 early-career scientists from low-and middle-income countries...

IVAC [to 26 Oct 2024]

https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html

Updates; Events

No new digest content identified.

IVI [to 26 Oct 2024] http://www.ivi.int/ IVI News & Announcements No new digest content identified.

Johns Hopkins Center for Health Security [to 26 Oct 2024]

https://centerforhealthsecurity.org/newsroom

Center News [Selected]

No new digest content identified.

MSF/Médecins Sans Frontières [to 26 Oct 2024]

http://www.msf.org/

Latest [Selected Announcements]

Lebanon

Beyond survival: Helping children and adults cope with the traumas of war in Lebanon

Project Update 22 Oct 2024

National Academy of Medicine - USA [to 26 Oct 2024]

https://nam.edu/programs/

News [Selected]

National Academy of Medicine Elects 100 New Members

October 21, 2024

National Academies-Sciences-Engineering-Medicine [NASEM]- USA [to 26 Oct 2024]

https://www.nationalacademies.org/newsroom

News

No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 26 Oct 2024]

https://www.hhs.gov/vaccines/about/index.html Upcoming Meetings/Latest Updates No new digest content identified.

NIH [to 26 Oct 2024] http://www.nih.gov/ News Releases No new digest content identified.

PATH [to 26 Oct 2024]

https://www.path.org/media-center/

Newsroom

<u>Unitaid and partners launch first-of-its-kind regional manufacturing initiative to improve</u> access to medical oxygen in sub-Saharan Africa

Oct 2024

Sabin Vaccine Institute [to 26 Oct 2024]

https://www.sabin.org/press/ Latest News & Press Releases No new digest content identified.

UNAIDS [to 26 Oct 2024]

http://www.unaids.org/en News, Stories, Updates Feature story

<u>Peru approves groundbreaking law to extend health coverage for migrants with HIV and TB</u>

21 October 2024

In a milestone decision, the Peruvian Congress has passed legislation that extends temporary health insurance coverage to migrants diagnosed with HIV and tuberculosis (TB). This law allows non-resident foreigners to access healthcare services through the public health insurance system (known by the Spanish acronym SIS) while they complete their immigration processes...

UNICEF [to 26 Oct 2024]

https://www.unicef.org/media/press-releases

Latest press releases, news notes and statements Statement 25 October 2024

<u>UN agencies warn of spiraling Sudan crisis as civilians face grave risks and famine threat grows amid access barriers</u>

PORT SUDAN, 25 October 2024 "The humanitarian crisis in Sudan continues to spiral, with millions of people in desperate need of assistance. The conflict has displaced over 11 million people, both internally and across borders, while pushing millions more into extreme vulnerability, particularly childre...

Remarks 25 October 2024

Dying in waiting: Gaza's children face lethal delays in medical evacuation

GENEVA, 25 October 2024 - "Children are being medically evacuated from Gaza at a rate of fewer than one child per day. If this lethally slow pace continues, it would take more than seven years to evacuate the 2,500 children needing urgent medical care. "As a result, children in Gaza are dying – not just fro...

Press release 23 October 2024

85 per cent of children affected by polio in 2023 lived in fragile and conflict-affected countries

NEW YORK, 24 October 2024 — Of the 541 children affected by polio globally in 2023, 85 per cent live in the 31 fragile, conflict-affected, and vulnerable countries, according to a new UNICEF analysis on World Polio Day. Polio cases in these settings have more than doubled in the past five years, while routine chil...

Press release 23 October 2024

<u>Intense bombardments, mass displacements and lack of access in northern Gaza force the</u> postponement of polio vaccination campaign

EAST JERUSALEM/AMMAN/GENEVA; 23 October 2024 - Due to the escalating violence, intense bombardment, mass displacement orders, and lack of assured humanitarian pauses across most of northern Gaza, the Polio Technical Committee for Gaza, including the Palestinian Ministry of Health, World Health Organization (W...

Remarks 22 October 2024

<u>UNICEF Executive Director Catherine Russell briefing to the United Nations Security</u> Council on the humanitarian situation in Haiti

NEW YORK, 22 October 2024 – "Excellencies, colleagues ... good afternoon. It is good to be with you for this important discussion on the deepening humanitarian crisis in Haiti. "I would like to express my appreciation to Ambassador Pascale Baeriswyl for hosting this briefing during Switzerland's Security Council pre...

Unitaid [to 26 Oct 2024] https://unitaid.org/ Featured News

22 October 2024

<u>Unitaid and partners launch first-of-its-kind regional manufacturing initiative to improve access to medical oxygen in sub-Saharan Africa</u>

Vaccine Equity Cooperative [nee Initiative] [to 26 Oct 2024]

https://vaccineequitycooperative.org/news/

News

Vaccination Acceptance & Demand Initiative [Sabin) [to 26 Oct 2024]

https://www.vaccineacceptance.org/ Announcements, Blog No new digest content identified.

Vaccine Confidence Project [to 26 Oct 2024]

http://www.vaccineconfidence.org/ News, Research and Reports No new digest content identified.

Vaccine Education Center – Children's Hospital of Philadelphia [to 26 Oct 2024]

http://www.chop.edu/centers-programs/vaccine-education-center
News

No new digest content identified.

Wellcome Trust [to 26 Oct 2024]

https://wellcome.org/news/all News. Opinion, Reports No new digest content identified.

The Wistar Institute [to 26 Oct 2024]

https://www.wistar.org/news/press-releases

Press Releases

No new digest content identified.

World Bank [to 26 Oct 2024]

http://www.worldbank.org/en/news/all

All News [Selected]

No new digest content identified.

WFPHA: World Federation of Public Health Associations [to 26 Oct 2024]

https://www.wfpha.org/

Blog, Events

No new digest content identified.

World Medical Association [WMA] [to 26 Oct 2024]

https://www.wma.net/news-press/press-releases/

Press Releases

The World Medical Association General Assembly 2024 in summary

23.10.2024

...[In addition to the revised Declaration of Helsinki, other declarations, resolutions and statements adopted by the WMA General Assembly include:

- WMA Resolution on anti-LGBTQ legislation
- WMA Resolution on Plastics and Health
- WMA Declaration on Prevention and Reduction of Air Pollution to Improve Air Quality
- WMA Resolution on the Protection of Healthcare in Israel and Gaza
- WMA Statement on Epidemics and Pandemics
- WMA Resolution in support of the Turkish Medical Association
- WMA Statement on Human Papillomavirus Vaccination
- WMA Statement on Adolescent Suicide
- WMA Resolution on Organ Donation in Prisoners
- WMA Declaration of Kigali on the Ethical Use of Medical Technology
- WMA Statement on Assisted Reproductive Technologies
- WMA Resolution on the Revocation of WHO Guidelines on Opioid Use
- WMA Guidelines on Promotional Mass Media Appearances by Physicians

World Organisation for Animal Health [OIE] [to 26 Oct 2024]

https://www.oie.int/

Press Releases, Statements

Global Events

Webinar: Launch of Competency and Curricula guidelines for Community Animal Health

Workers

From 22/10/2024 to 22/10/2024

:::::: ::::::

ARM [Alliance for Regenerative Medicine] [to 26 Oct 2024]

https://alliancerm.org/press-releases/

Selected Press Releases

No new digest content identified.

BIO [to 26 Oct 2024]

https://www.bio.org/press-releases

Press Releases

No new digest announcements identified.

DCVMN – Developing Country Vaccine Manufacturers Network [to 26 Oct 2024]

http://www.dcvmn.org/

News; Upcoming events

No new digest announcements identified.

ICBA – International Council of Biotechnology Associations [to 26 Oct 2024]

https://internationalbiotech.org/news/

News

No new digest announcements identified.

IFPMA [to 26 Oct 2024]

https://ifpma.org/

News, Statements [Selected] Statement 21 Oct 2024

<u>Opening statement at COP 16: Multilateral mechanism (MLM) for digital sequence information (DSI)</u>

By IFPMA [Excerpt]

... However, we have serious concerns about the current proposals for a tax-based Multilateral Mechanism (MLM) for DSI under the CBD. These proposals could undermine the objectives they aim to support by introducing regulatory and financial barriers that would stifle innovation, delay R&D, and complicate compliance. A tax-based MLM would increase costs across the board, disproportionately impacting cutting-edge sectors that may rely on efficient access to DSI to drive innovation.

The proposed mechanism risks creating legal uncertainties by enforcing requirements on a framework that lacks a clear and universally accepted definition of DSI. This could result in fragmented national regulations, creating a patchwork of rules that will be detrimental to innovation. Moreover, the proposed system will not necessarily ensure freedom to operate, as national access and benefit-sharing (ABS) laws would still apply, further complicating the landscape for researchers and innovators.

It is crucial to emphasize that industry already engages in substantial benefit-sharing through voluntary initiatives, which include capacity building, technology transfer, and preferential pricing. The proposed MLM does not adequately recognize these, as well as various existing contributions by various industrial sectors that are already delivering tangible benefits...

International Alliance of Patients' Organizations – IAPO [to 26 Oct 2024]

https://www.iapo.org.uk/news Press and media [Selected] No new digest announcements identified.

International Generic and Biosimilar Medicines Association [IGBA]

https://www.igbamedicines.org/ News

No new digest announcements identified.

PhRMA [to 26 Oct 2024]
http://www.phrma.org/
Press Releases
No new digest announcements identified.

::::::

Vaccines/Therapeutics/Medicines - Selected Developer/Manufacturer Announcements

AstraZeneca

<u>Press Releases</u> - No new digest announcements identified

Bavarian Nordic

Latest News - No new digest announcements identified

Bharat Biotech

<u>Press Releases</u> - No new digest announcements identified

BioCubaFarma - Cuba

<u>Últimas Noticias</u> - No new digest announcements identified

Biological E

<u>News</u> - No new digest announcements identified

BioNTech

<u>Press Releases</u> - No new digest announcements identified

Boehringer

<u>Press Releases</u> - No new digest announcements identified

CanSinoBIO

<u>News</u> - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified.

Cinnagen

Recent News - No new digest announcements identified.

Clover Biopharmaceuticals – China

News - No new digest announcements identified.

Curevac

News - No new digest announcements identified.

Gamaleya National Center/Sputnik

<u>Latest News and Events</u> - No new digest announcements identified [Last: 09 Nov 2020] https://sputnikvaccine.com/ - No new digest announcements identified [Last: 31 Aug 2022]

GSK

Press releases for media

24 October 2024

New data for Arexvy, GSK's respiratory syncytial virus vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease

Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD.

EuBiologics, S Korea

News - No new digest announcements identified.

IMBCAMS, China

Home - Website not responding at inquiry.

Janssen/JNJ

<u>Press Releases</u> - No new digest announcements identified.

Merck

News releases

October 23, 2024

CDC'S ACIP Recommends Merck's CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older

Moderna

<u>Press Releases</u> - No new digest announcements identified

Nanogen

News - No new digest announcements identified

Novartis

<u>News</u> - No new digest announcements identified.

Novavax

<u>Press Releases</u> Oct 24, 2024 Statement COVID-19

U.S. CDC and ACIP Recommend Additional COVID-19 Vaccine Dose for Older Individuals and Those Who Are Immunocompromised

Pfizer

Recent Press Releases

10.23.2024

Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

10.22.2024

<u>U.S. FDA Approves Pfizer's RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased</u>
Risk for Disease

R-Pharm

https://rpharm-us.com/index.php [No news or media page identified]

Sanofi Pasteur

Press Releases

October 25, 2024

<u>Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine</u> sales; 2024 business EPS guidance raised due to strong business performance

:: Vaccines sales up 25.5%, boosted by phasing of flu sales, and by Beyfortus due to approved extra capacity

Serum Institute of India

NEWS & ANNOUNCEMENTS

<u>SLS Europe and Bilthoven Biologicals receive positive CHMP Opinion for SIILTIBCY® – a novel Tuberculosis Skin Test in Europe</u>

Oct 23, 2024

SIILTIBCY® is poised to be the first skin test in Europe that accurately detects TB, regardless of BCG vaccination status.

Sinopharm/WIBPBIBP

<u>News</u> - No new digest announcements identified

Sinovac

<u>Press Releases</u> - No new digest announcements identified.

SK Biosciences

Press Releases

SK bioscience Receives Approval of Quadrivalent Influenza Vaccine in Indonesia

This approval paves the way for exports to the world's fourth most populous country. 2024.10.23

Takeda

<u>Newsroom</u> - No new digest announcements identified.

Valneva

<u>Press Releases</u> October 21, 2024

Valneva to Present on Chikungunya at Several Leading Scientific Conferences

Vector State Research Centre of Viralogy and Biotechnology

<u>Home</u> - [Website not responding [404 error]

WestVac Biopharma

<u>Media</u> - No new digest announcements identified.

Zhifei Longcom, China

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] <u>Website</u> [No News/Announcements page identified]

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: <u>WHO</u>
- :: Organization Announcements
- :: Journal Watch
- :: Pre-Print Servers

::::::

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics

Volume 15, 2023 Issue 4

https://www.tandfonline.com/toc/uabr21/current

Article

<u>Procedural Dimensions of Religious Exemptions to Covid-19 Vaccine Mandates: Promoting Clarity, Fairness, and Transparency in Applications</u>

<u>Hajung Lee</u> Pages: 246-261

Published online: 26 Apr 2024

Article

<u>"Ethical Responsibility Very Often Gets Drowned Out": A Qualitative Interview Study of Genome Scientists' and ELSI Scholars' Perspectives on the Role and Relevance of ELSI Expertise</u>

Daphne O. Martschenko, Anna Granucci & Mildred K. Cho

Pages: 312-323

Published online: 25 Jun 2024

Article

Pediatric Assent in Clinical Practice: A Critical Scoping Review

Jason Adam Wasserman, Amelia N. Najor, Natalie Liogas, Stephanie M. Swanberg, Abram Brummett,

Naomi T. Laventhal & Mark Christopher Navin

Pages: 336-346

Published online: 21 Aug 2024

AMA Journal of Ethics

Volume 26, Number 10: E745-821

https://journalofethics.ama-assn.org/issue/sleep-stewardship

Sleep Stewardship

Sleep hygiene, causes of sleep disruption, and sleep disorder interventions are recent, important topics of health and cultural awareness. The better one's sleep quality over their lifespan, the better their health status and health outcomes, so who has reliable access to quality sleep is not just a clinical matter, but one for ethics and justice. This theme issue's focus is broader than poor sleep pathologies and investigates how sleep is, perhaps, best conceived as a communal, natural resource. We all need clean air and water, shelter, nutritionally dense food, and sleep. Of course, we sleep as individuals, but our common human interest in quality sleep of sufficient duration generates collective obligations to respond equitably to chronic health conditions that exacerbate poor sleep patterns; to support conditions for feeling safe, peaceful, and calm enough to rest; and to mitigate noise and light pollution that compromise our and our neighbors' sleep environments.

American Journal of Human Genetics

Oct 03, 2024 Volume 111 Issue 10 p2071-2306

https://www.cell.com/ajhg/current

This month in *The Journal*

Alyson B. Barnes, Kylee L. Spencer

Genome-wide association studies have shown that the effect sizes of many causal variants are strongly correlated across ancestries, but this is not true for all variants. Some differences could be explained by variation in gene regulation, but it has been challenging to determine whether ancestry-specific levels of gene expression are due to differences in allele frequencies, environmental effects, interplay between the two, or simply false positives. In this issue, Wang et al. identify genes differentially expressed across ancestries (ancDE) by leveraging single-cell RNA-sequencing data for individuals with either East Asian or European ancestries.

[Reviewed earlier]

American Journal of Infection Control

November 2024 Volume 52 Issue 11 p1227-1344 http://www.ajicjournal.org/current

Major Articles

The effectiveness of vaccination on the COVID-19 epidemic in California

Elijah Huang, et al.

Published online: May 30, 2024

p1252-1257

American Journal of Preventive Medicine

November 2024 Volume 67 Issue 5 p641-802

https://www.ajpmonline.org/current

Research Articles

Zoster Vaccine Lowers Stroke and Myocardial Infarction Risk in Chronic Disease

Matthew F. Helm, et al.

Published online: June 21, 2024

p676-683

American Journal of Public Health

November 2024 114(11)

http://ajph.aphapublications.org/toc/ajph/current

[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene

Volume 111 (2024): Issue 4 (Oct 2024)

https://www.ajtmh.org/view/journals/tpmd/111/4/tpmd.111.issue-3.xml

[Reviewed earlier]

Annals of Internal Medicine

October 2024 Volume 177, Issue 10

https://www.acpjournals.org/toc/aim/current

[Reviewed earlier]

Artificial Intelligence – An International Journal

Volume 335 October 2024

https://www.sciencedirect.com/journal/artificial-intelligence/vol/335/suppl/C

[Reviewed earlier]

BMC Cost Effectiveness and Resource Allocation

http://resource-allocation.biomedcentral.com/

(Accessed 26 Oct 2024)

[No new digest content identified]

BMC Health Services Research

http://www.biomedcentral.com/bmchealthservres/content

(Accessed 26 Oct 2024)

<u>Provider and community perceptions of integrated COVID-19 and routine childhood immunisation programmes in Nigeria: a qualitative exploratory study</u>

In Nigeria, COVID-19 vaccines were delivered through outreach activities, as well as integrated within routine immunisation. However, evaluations of integrated approaches for novel vaccines are scarce. We aime...

Authors: Ayobami A. Bakare, Kofoworola O. Akinsola, Carina King, Abiodun A. Sogbesan, Oluwabunmi R. Bakare, Opeyemi Y. Fadahunsi, Julius Salako, Adegoke G. Falade and Sibylle Herzig van Wees

Citation: BMC Health Services Research 2024 24:1262 Content type: Research Published on: 21 October 2024

BMC Infectious Diseases

http://www.biomedcentral.com/bmcinfectdis/content (Accessed 26 Oct 2024)

Effect of 10-valent pneumococcal conjugate vaccine on trends of pneumococcal meningitis in children under five years, Uganda, 2003–2022

Pneumococcal meningitis, a vaccine-preventable disease caused by Streptococcus pneumoniae (Spn) is the leading bacterial meningitis in under five children. In April 2014, Uganda introduced routine immunization wi...

Authors: Yasiini Nuwamanya, Immaculate Ampeire, Michael Baganizi, Ritah Atugonza, Fred Nsubuga, Benon Kwesiga, Richard Migisha, Lilian Bulage, Daniel Kadobera, Alex Riolexus Ario and Annet Kisakye

Citation: BMC Infectious Diseases 2024 24:1187

Content type: Research Published on: 21 October 2024

BMC Medical Ethics

http://www.biomedcentral.com/bmcmedethics/content (Accessed 26 Oct 2024) [No new digest content identified]

BMC Medicine

http://www.biomedcentral.com/bmcmed/content (Accessed 26 Oct 2024) [No new digest content identified]

BMC Pregnancy and Childbirth

http://www.biomedcentral.com/bmcpregnancychildbirth/content (Accessed 26 Oct 2024) [No new digest content identified]

BMC Public Health

http://bmcpublichealth.biomedcentral.com/articles (Accessed 26 Oct 2024)

<u>Burden of vaccine-preventable diseases in adults (50+) in the United States: a retrospective claims analysis</u>

In adults aged 50 + years, vaccine-preventable diseases (VPDs) pose a significant health burden and can lead to additional 'downstream effects' of infection beyond the acute phase e.g., increasing the risk for...

Authors: Maximilian Hartmann, Nathalie Servotte, Emmanuel Aris, T. Mark Doherty, Ahmed Salem and

Ekkehard Beck

Citation: BMC Public Health 2024 24:2960

Content type: Research Published on: 25 October 2024

Factors influencing vaccination up-take among nomadic population in four regions of Ghana: a qualitative study

Vaccination has contributed to the reduction in vaccine preventable diseases. Despite, improved global coverage, vaccination among nomadic populations is still low especially in Africa. This study explored fac...

Authors: Samuel Afari-Asiedu, Lawrence Gyabaa Febir, Charlotte Tawiah, Semeeh Omoleke, Porbilla Ofosu-Apea, Felix Osei-Sarpong, Antoine Marie Cyrille Ziao, Charles Kyei, Edward Anane Apraku, Augustine Antwi, Chrysantus Kubio, Anthony Adofo Ofosu, Peter Gyamfi Kwarteng, Mrunal Shetye and Kwaku Poku Asante

Citation: BMC Public Health 2024 24:2921

Content type: Research Published on: 22 October 2024

<u>Serious adverse events following immunization with COVID-19 vaccines in Lebanon: a retrospective analysis of the National Pharmacovigilance Database</u>

Continuous surveillance and risk assessment of inactivated Coronavirus Disease 2019 (COVID-19)) vaccines provide an understanding of their safety profiles, guide vaccination strategy and public health policy. ...

Authors: Rita Karam, Katia Iskandar, Myriam Watfa and Abeer Zeitoun

Citation: BMC Public Health 2024 24:2905

Content type: Research Published on: 21 October 2024

COVID-19 vaccine hesitancy in Ethiopia: a latent class analysis

Despite evidence demonstrating the effectiveness of the COVID-19 vaccine, vaccine hesitancy has emerged as a major challenge for vaccine uptake. The objective of this study was to classify latent typologies of...

Authors: Aderaw Anteneh, Anteneh Getachew, Misael Kenera, Amel Salim, Fethia Kedir, Bekele

Belayihun and Erica Felker-Kantor

Citation: BMC Public Health 2024 24:2894

Content type: Research Published on: 21 October 2024

BMC Research Notes

http://www.biomedcentral.com/bmcresnotes/content (Accessed 26 Oct 2024) [No new digest content identified]

BMJ Evidence-Based Medicine

October 2024 - Volume 29 - 5 https://ebm.bmj.com/content/29/5 [Reviewed earlier] September 2024 - Volume 9 - 9 https://gh.bmj.com/content/9/9 [Reviewed earlier]

Bulletin of the Atomic Scientists

September 2024 https://thebulletin.org/magazine/2024-09/ [Reviewed earlier]

Bulletin of the World Health Organization

Volume 102(10); 2024 Oct 1 https://www.ncbi.nlm.nih.gov/pmc/issues/471305/ [Reviewed earlier]

Cell

Oct 17, 2024 Volume 187 Issue 21 p5797-6124 https://www.cell.com/cell/current

50th Anniversary

The expanding world of neuroscience

The Cell editorial team

Understanding the brain fascinates and intrigues many across the world. In this 50th Anniversary "Focus on Neuroscience" issue, we present Leading Edge content reflecting on the progress of the field, highlighting emerging topics, and paving the way toward many more years of exciting neuroscience research.

Child Care, Health and Development

Volume 50, Issue 6 November 2024 https://onlinelibrary.wiley.com/toc/13652214/current [Reviewed earlier]

Clinical Pharmacology & Therapeutics

Volume 116, Issue 4 Pages: 875-1142 October 2024 https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

Issue Focus: Pharmacogenomics and Precision Medicine
[Reviewed earlier]

Clinical Therapeutics

September 2024 Volume 46 Issue 9 p661-726 http://www.clinicaltherapeutics.com/current [Reviewed earlier]

Clinical Trials

Volume 21 Issue 5, October 2024 https://journals.sagepub.com/toc/ctja/21/5 [New issue; No digest content identified]

Conflict and Health

http://www.conflictandhealth.com/ [Accessed 26 Oct 2024] [No new digest content identified]

Contemporary Clinical Trials

Volume 145 October 2024

https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/145/suppl/C

[New issue; No digest content identified]

The CRISPR Journal

Volume 7, Issue 5 / October 2024

https://www.liebertpub.com/toc/crispr/7/5

Perspectives Open Access

Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative

Jon Rueda, Íñigo de Miguel Beriain, and Lluis Montoliu

Pages:220-226

Published Online:10 October 2024

https://doi.org/10.1089/crispr.2024.0042

Abstract

Casgevy, the world's first approved CRISPR-based cell therapy, has been priced at \$2.2 million per patient. Although this hefty price tag was widely anticipated, the extremely high cost of this and other cell and gene therapies poses a major ethical issue in terms of equitable access and global health. In this Perspective, we argue that lowering the prices of future CRISPR therapies is an urgent ethical imperative. Although we focus on Casgevy as a case study, much of our analysis can be extrapolated to the controversies over affordable access to other gene and cell therapies. First, we explain why this first-of-its-kind CRISPR therapy might be so expensive. We then analyze the ethical issues of equity and global health of early CRISPR treatments. Next, we discuss potential solutions to lower the prices of CRISPR gene therapies. We conclude that the approval of CRISPR transforms our obligations of justice and compels us to bring future gene therapies to the maximum possible number of patients with serious genetic diseases at affordable prices.

Current Genetic Medicine Reports

Volume 11, Issue 3-4 December 2023 https://link.springer.com/journal/40142/volumes-and-issues/11-3 [Reviewed earlier]

Current Medical Research and Opinion

Volume 40, Issue 8 2024 https://www.tandfonline.com/toc/icmo20/current [Reviewed earlier]

Current Opinion in Infectious Diseases

October 2024 - Volume 37 - Issue 5

https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx

[Reviewed earlier]

Current Protocols in Human Genetics

https://currentprotocols.onlinelibrary.wiley.com/journal/19348258 [Accessed 26 Oct 2024] [No new digest content identified]

Developing World Bioethics

Volume 24, Issue 3 Pages: 135-261 September 2024 https://onlinelibrary.wiley.com/toc/14718847/current [Reviewed earlier]

Development in Practice

Volume 34, Issue 6, 2024 https://www.tandfonline.com/toc/cdip20/34/6 [Reviewed earlier]

Development Policy Review

Volume 42, Issue 5 September 2024 https://onlinelibrary.wiley.com/toc/14677679/current [Reviewed earlier]

Disaster Medicine and Public Health Preparedness

Volume 18 - 2024

https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue

[Reviewed earlier]

Disasters

Volume 48, Issue 4 October 2024 https://onlinelibrary.wiley.com/toc/14677717/2024/48/4 [Reviewed earlier]

EMBO Reports

Volume 25 Issue 10 10 October 2024 https://www.embopress.org/toc/14693178/current [Reviewed earlier]

Emerging Infectious Diseases

Volume 30, Number 11—November 2024 http://wwwnc.cdc.gov/eid/ [New issue; No digest content identified]

Epidemics

Volume 48 September 2024 https://www.sciencedirect.com/journal/epidemics/vol/48/suppl/C [Reviewed earlier]

Epidemiology and Infection

Volume 152 - 2024 https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue [Reviewed earlier]

Ethics & Human Research

Volume 46, Issue 5 Pages: 1-42 September—October 2024 *Enrolling invested parties in research :: Research on social networking sites* [Reviewed earlier]

Ethics & International Affairs

Volume 38 - Issue 1 - Spring 2024 https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue [Reviewed earlier]

Ethics, Medicine and Public Health

Volume 31 (December 2023) https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/31/suppl/C [Reviewed earlier]

The European Journal of Public Health

Volume 34, Issue 5, October 2024 https://academic.oup.com/eurpub/issue/34/5 [New issue; No digest content identified]

Expert Review of Vaccines

Vol 23 (1) 2023 https://www.tandfonline.com/toc/ierv20/current [Reviewed earlier]

Foreign Affairs

September/October 2024 Volume 103, Number 5 https://www.foreignaffairs.com/issues/2023/103/5 [Reviewed earlier]

Forum for Development Studies

Volume 51, 2024 - İssue 3 http://www.tandfonline.com/toc/sfds20/current [Reviewed earlier]

Frontiers in Medicine

https://www.frontiersin.org/journals/medicine/volumes?volume-id=1237 [Accessed 26 Oct 2024] [Reviewed earlier]

Genetics in Medicines

Volume 26, Issue 10 October 2024 https://www.sciencedirect.com/journal/genetics-in-medicine/vol/26/issue/10 [Reviewed earlier]

Genome Medicine

https://genomemedicine.biomedcentral.com/articles [Accessed 26 Oct 2024] [No new digest content identified]

Global Health Action

Volume 17, Issue 1 (2024) https://www.tandfonline.com/toc/zgha20/current?nav=tocList [Reviewed earlier]

Global Health: Science and Practice (GHSP)

Vol. 12, No. 4 August 27, 2024 http://www.ghspjournal.org/content/current [Reviewed earlier]

Global Legal Monitor & Legal Reports – Library of Congress/USA

https://www.loc.gov/collections/global-legal-monitor/
https://www.loc.gov/books/?q=legal+reports&fa=partof%3Alegal+reports+%28publications+of+the+l
aw+library+of+congress%29&sb=date_desc
[Accessed 26 Oct 2024]
[No new digest content identified]

Global Public Health

Volume 19, Issue 1 (2024) http://www.tandfonline.com/toc/rgph20/current [Reviewed earlier]

Globalization and Health

http://www.globalizationandhealth.com/ [Accessed 26 Oct 2024] [No new digest content identified]

Health and Human Rights

Volume 26, Issue 1, June 2024 https://www.hhrjournal.org/volume-26-issue-1-june-2024/ **SPECIAL SECTION — COMMEMORATING 30 YEARS**

[Reviewed earlier]

Health Economics, Policy and Law

Volume 19 - Issue 2 - April 2024 https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue [Reviewed earlier]

Health Policy and Planning

Volume 39, Issue 9, November 2024 https://academic.oup.com/heapol/issue/39/9 [New issue; No digest content identified]

Health Research Policy and Systems

http://www.health-policy-systems.com/content [Accessed 26 Oct 2024] [No new digest content identified]

Human Gene Therapy

Volume 35, Issue 19-20 / October 2024 https://www.liebertpub.com/toc/hum/35/19-20 [Reviewed earlier]

Humanitarian Practice Network

https://odihpn.org/ Featured Publications [No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)

Volume 20 Issue 1, 2024 https://www.tandfonline.com/toc/khvi20/20/1?nav=tocList-selected Content [Reviewed earlier]

Immunity

Oct 08, 2024 Volume 57 Issue 10 p2251-2482 https://www.cell.com/immunity/current [Reviewed earlier]

Infectious Agents and Cancer

http://www.infectagentscancer.com/

[Accessed 26 Oct 2024]
[No new digest content identified]

Infectious Diseases of Poverty

http://www.idpjournal.com/content [Accessed 26 Oct 2024] [No new digest content identified]

International Health

Volume 16, Issue 5, September 2024 https://academic.oup.com/inthealth/issue/16/5 [Reviewed earlier]

International Human Rights Law Review

Volume 13 (2024): Issue 1 (Jun 2024): https://brill.com/view/journals/hrlr/13/1/hrlr.13.issue-1.xml

**Special Issue on Inter-State Communications

*Table of Contents

[Reviewed earlier]

International Journal of Community Medicine and Public Health

Vol. 11 No. 10 (2024): October 2024 https://www.ijcmph.com/index.php/ijcmph/issue/view/117 [Reviewed earlier]

International Journal of Epidemiology

Volume 53, Issue 4, August 2024 https://academic.oup.com/ije/issue/53/4 [Reviewed earlier]

International Journal of Human Rights in Healthcare

Volume 17 Issue 4 2024 https://www.emerald.com/insight/publication/issn/2056-4902/vol/17/iss/4 Table of contents [Reviewed earlier]

JAMA

October 22/29, 2024, Vol 332, No. 16, Pages 1315-1404 https://jamanetwork.com/journals/jama/currentissue Special Communication
Integrating Clinical Trials and Practice

<u>Modernizing the Data Infrastructure for Clinical Research to Meet Evolving Demands for Evidence</u>

Joseph B. Franklin, JD, PhD; Caroline Marra, PhD; Kaleab Z. Abebe, PhD; et al. free access has active quiz has multimedia

JAMA. 2024;332(16):1378-1385. doi:10.1001/jama.2024.0268

This Special Communication proposes expanding clinical research to include rigorous evaluation of multiple data sources and types and to enable reuse of health data for many purposes to produce evidence about medical interventions.

<u>Video:</u> Envisioning a Path Forward for Clinical Trials—JAMA Summit Keynote Presentation by Amy P. Abernethy, MD, PhD

JAMA Health Forum

October 2024, Vol 5, No. 10 https://jamanetwork.com/journals/jama-health-forum/issue [Reviewed earlier]

JAMA Pediatrics

October 2024, Vol 178, No. 10, Pages 959-1086 https://jamanetwork.com/journals/jamapediatrics/currentissue [Reviewed earlier]

JBI Evidence Synthesis

September 2024 - Volume 22 - Issue 9 https://journals.lww.com/jbisrir/Pages/currenttoc.aspx [Reviewed earlier]

Journal of Adolescent Health

October 2024 Volume 75 Issue 4 p525-690 https://www.jahonline.org/current [Reviewed earlier]

Journal of Artificial Intelligence Research

Vol. 81 (2024)
https://www.jair.org/index.php/jair
Contents
[Reviewed earlier]

Journal of Community Health

Volume 49, Issue 5 October 2024 https://link.springer.com/journal/10900/volumes-and-issues/49-5 [Reviewed earlier]

Journal of Current Medical Research and Opinion

...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.

Vol. 7 No. 01 (2024), January 2, 2024, Page 1988-1996

https://www.cmro.in/index.php/jcmro/issue/view/75

[Reviewed earlier]

Journal of Development Economics

Volume 171 October 2024

https://www.sciencedirect.com/journal/journal-of-development-economics/vol/171/suppl/C

[New issue; No digest content identified]

Journal of Empirical Research on Human Research Ethics

Volume 19 Issue 3, July 2024

http://journals.sagepub.com/toc/jre/current

Special Issues in Research and IRB/REC Functioning, Including the use of AI

[Reviewed earlier]

Journal of Epidemiology & Community Health

October 2024 - Volume 78 - 10

https://jech.bmj.com/content/78/10

[Reviewed earlier]

Journal of Evidence-Based Medicine

Volume 17, Issue 3 Pages: 469-687 September 2024

https://onlinelibrary.wiley.com/toc/17565391/current

[Reviewed earlier]

Journal of Global Ethics

Volume 20, Issue 2 (2024)

http://www.tandfonline.com/toc/rjge20/current

Special Issue: Climate Justice and the Global Development Crisis.

Guest Editors: Anna Malavisi, Tom Hilde, and Krushil Watene

[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)

Volume 35, Number 3, August 2024

https://muse.jhu.edu/issue/52935

Table of Contents

[Reviewed earlier]

Journal of Immigrant and Minority Health

Volume 26, Issue 5 October 2024

https://link.springer.com/journal/10903/volumes-and-issues/26-5

[Reviewed earlier]

Journal of Immigrant & Refugee Studies

Volume 22, 2024 Issue 3

https://www.tandfonline.com/toc/wimm20/current

[Reviewed earlier]

Journal of International Development

Volume 36, Issue 7 Pages: 3-2866 October 2024 https://onlinelibrary.wiley.com/toc/10991328/current [Reviewed earlier]

Journal of Medical Ethics

October 2024 - Volume 50 - 10 http://jme.bmj.com/content/current [Reviewed earlier]

Journal of Patient-Centered Research and Reviews

Volume 11, Issue 3 (2024) https://institutionalrepository.aah.org/jpcrr/ [New issue; No digest content identified]

The Journal of Pediatrics

Volume 273 October 2024 https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/273/suppl/C Discussion

Pediatric Research without Parental Permission

David Wendler Article 113896

Journal of Pharmaceutical Policy and Practice

Volume 17, Issue 1 (2024) https://www.tandfonline.com/toc/jppp20/17/1 [Reviewed earlier]

Journal of Public Health Management & Practice

September/October 2024 - Volume 30 - Issue 5 https://journals.lww.com/jphmp/pages/currenttoc.aspx [Reviewed earlier]

Journal of Public Health Policy

Volume 45, issue 3, September 2024 https://link.springer.com/journal/41271/volumes-and-issues/45-3 [Reviewed earlier]

Journal of the Royal Society - Interface

October 2024 Volume 21 Issue 219 https://royalsocietypublishing.org/toc/rsif/current [Reviewed earlier]

Journal of Travel Medicine

Volume 31, Issue 7, October 2024 https://academic.oup.com/jtm/issue Original Article

A randomized, placebo-controlled, blinded phase 1 study investigating a novel inactivated, Vero cell-culture derived Zika virus vaccineGet access

Nina V Wressnigg and others

<u>Combined immunogenicity evaluation for a new single-dose live-attenuated chikungunya vaccineGet access</u>

Vera Buerger and others

Perspective Editor's Choice

Three RSV vaccines now recommended for many older adults; what about travellers?

David O Freedman and Camille N Kotton

Journal of Virology

Volume 98 Number 9 September 2024 http://jvi.asm.org/content/current [Reviewed earlier]

The Lancet

Oct 19, 2024 Volume 404 Number 10462 p1493-1614 https://www.thelancet.com/journals/lancet/issue/current [New issue; No digest content identified]

The Lancet Child & Adolescent Health

Oct 2024 Volume 8 Number 10 p707-792, e12-e15 https://www.thelancet.com/journals/lanchi/issue/current [Reviewed earlier]

Lancet Digital Health

Oct 2024 Volume 6 Number 10 e673-e771 https://www.thelancet.com/journals/landig/issue/current [Reviewed earlier]

Lancet Global Health

Oct 2024 Volume 12 Number 10 e1560-e1736 https://www.thelancet.com/journals/langlo/issue/current [Reviewed earlier]

Lancet Infectious Diseases

Oct 2024 Volume 24 Number 10 p1059-1176, e602-e659 https://www.thelancet.com/journals/laninf/issue/current

[Reviewed earlier]

Lancet Public Health

Oct 2024 Volume 9 Number 10 e709-e830 https://www.thelancet.com/journals/lanpub/issue/current [Reviewed earlier]

Lancet Respiratory Medicine

Oct 2024 Volume 12 Number 10 p743-836, e57-e64 https://www.thelancet.com/journals/lanres/issue/current [Reviewed earlier]

Maternal and Child Health Journal

Volume 28, Issue 10 October 2024 https://link.springer.com/journal/10995/volumes-and-issues/28-10 [Reviewed earlier]

Medical Decision Making (MDM)

Volume 44 Issue 7, October 2024 http://mdm.sagepub.com/content/current [Reviewed earlier]

The Milbank Quarterly

A Multidisciplinary Journal of Population Health and Health Policy Volume 102, Issue 3 Pages: 517-821 September 2024 https://onlinelibrary.wiley.com/toc/14680009/current [Reviewed earlier]

Molecular Therapy

Oct 02, 2024 Volume 32 Issue 10 p3195-3746 https://www.cell.com/molecular-therapy/current [Reviewed earlier]

Nature

Volume 634 Issue 8035, 24 October 2024 https://www.nature.com/nature/volumes/633/issues/8035 Perspective 23 Oct 2024

The importance of family-based sampling for biobanks

This Perspective discusses the strengths and limitations of future biobank sampling strategies based on oversampling close relatives as opposed to the current population-based approach.

Neil M. Davies, Gibran Hemani, Matthew C. Keller

Nature Biotechnology

Volume 42 Issue 10, October 2024

https://www.nature.com/nbt/volumes/42/issues/10 [Reviewed earlier]

Nature Communications

https://www.nature.com/subjects/health-sciences/ncomms (Accessed26 Oct 2024) [No new digest content identified]

Nature Genetics

Volume 56 Issue 9, September 2024 https://www.nature.com/ng/volumes/56/issues/9 [Reviewed earlier]

Nature Human Behaviour

Volume 8 Issue 10, October 2024 https://www.nature.com/nathumbehav/volumes/8/issues/10 Editorial 22 Oct 2024

Embracing the ubiquity of machines

As digital technologies become ever more pervasive and sophisticated, understanding the nuances of the relationship between humans and machines becomes increasingly important. Spanning a range of disciplines, from computer science and psychology to medicine and education, this issue's Focus includes a diverse array of voices and perspectives on the many ways in which humans and digital machines interact and communicate with each other, as well as the societal implications and ethical considerations of emerging technologies.

Nature Medicine

Volume 30 Issue 10, October 2024 https://www.nature.com/nm/volumes/30/issues/10 [Reviewed earlier]

Nature Reviews Drug Discovery

Volume 23 Issue 10, October 2024 https://www.nature.com/nrd/volumes/23/issues/10 [Reviewed earlier]

Nature Reviews Genetics

Volume 25 Issue 10, October 2024 https://www.nature.com/nrg/volumes/25/issues/10 [Reviewed earlier]

Nature Reviews Immunology

Volume 24 Issue 10, October 2024 https://www.nature.com/nri/volumes/24/issues/10 [Reviewed earlier]

New England Journal of Medicine

Volume 391 No. 16 October 24, 2024

https://www.nejm.org/toc/nejm/medical-journal

[New issue; No digest content identified]

NEJM Evidence

Volume 3 No. 10 October 2024

https://evidence.nejm.org/toc/evid/current

NEJM Evidence, a new monthly digital journal from NEJM Group, presents innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.

[Reviewed earlier]

njp Vaccines

https://www.nature.com/npjvaccines/ [Accessed 26 Oct 2024] [Reviewed earlier]

Pediatrics

Volume 154, Issue 4 October 2024 https://publications.aap.org/pediatrics/issue/154/4 Articles [Reviewed earlier]

PharmacoEconomics

Volume 42, Issue 10 October 2024 https://link.springer.com/journal/40273/volumes-and-issues/42-10 [Reviewed earlier]

PLoS Biology

https://journals.plos.org/plosbiology/ (Accessed 26 Oct 2024) [No new digest content identified]

PLoS Genetics

https://journals.plos.org/plosgenetics/ (Accessed 26 Oct 2024) [No new digest content identified]

PLoS Global Public Health

https://journals.plos.org/globalpublichealth/search?sortOrder=DATE NEWEST FIRST&filterStartDate=2 021-10-01&filterJournals=PLOSGlobalPublicHealth&q=&resultsPerPage=60 (Accessed 26 Oct 2024)

<u>Promising results of HIV prevention trials highlight the benefits of collaboration in global</u> <u>health: The perspective of the Forum HIV Recency Assay Working Group</u> Robin Schaefer, Logan Donaldson, Mitchell Leus, Chukwunomso E. Osakwe, Benjamin Chimukangara, Shona Dalal, Ann Duerr, Fei Gao, David V. Glidden, Beatriz Grinsztejn, Jessica Justman, Grace Kumwenda, Oliver Laeyendecker, Ha Youn Lee, Frank Maldarelli, Kenneth H. Mayer, Jeffrey Murray, Bharat S. Parekh, Brian Rice, Michael N. Robertson, Suzue Saito, Vani Vannappagari, Mitchell Warren, Diana Zeballos, Jörg Zinserling, Veronica Miller Opinion | published 24 Oct 2024 PLOS Global Public Health

https://doi.org/10.1371/journal.pgph.0003878

PLoS Medicine

https://journals.plos.org/plosmedicine/ (Accessed 26 Oct 2024) [No new digest content identified]

PLoS Neglected Tropical Diseases

http://www.plosntds.org/ (Accessed 26 Oct 2024) [No new digest content identified]

PLoS One

http://www.plosone.org/ [Accessed 26 Oct 2024]

<u>Cross-cultural adaptation and validation of an Urdu version of the Vaccine Attitudes</u> <u>Examination (VAX-U) scale</u>

Atta Abbas Naqvi, Md. Ashraful Islam, Amnah Jahangir, Mehwish Rizvi, Wajiha Iffat, Muhammad Tariq Aftab, Leslie R. Martin

Research Article | published 25 Oct 2024 PLOS ONE

https://doi.org/10.1371/journal.pone.0312459

<u>Prevalence of caregiver hesitancy for vaccinations in children and its associated factors: A systematic review and meta-analysis</u>

Nur Hasnah Maamor, Nor Asiah Muhamad, Nor Soleha Mohd Dali, Fatin Norhasny Leman, Izzah Athirah Rosli, Tengku Puteri Nadiah Tengku Bahrudin Shah, Nurul Hidayah Jamalluddin, Nurul Syazwani Misnan, Zuraifah Asrah Mohamad, Sophia Karen Bakon, Mohd Hatta Abdul Mutalip, Muhammad Radzi Abu Hassan, Nai Ming Lai

Research Article | published 24 Oct 2024 PLOS ONE

https://doi.org/10.1371/journal.pone.0302379

<u>Effects of religion, politics and distance to providers on HPV vaccine attitudes and intentions of parents in rural Utah</u>

Abigail A. Lee, Ty J. Skyles, Jamie L. Jensen, Brandon Ord, Spencer C. Davis, Matthew J. East, A. Eli Asay, Acelan M. Obray, Tess Syndergaard, Tyler Davis, Bryce U. Nielson, Ruth J. Larson, Dashiell S. Miner, Kaitlyn Hinton, Lydia Zentz, Lydia Busacker, Brian D. Poole

Research Article | published 23 Oct 2024 PLOS ONE

https://doi.org/10.1371/journal.pone.0312549

PLoS Pathogens

http://journals.plos.org/plospathoge ns/ [Accessed 26 Oct 2024]

PNAS - Proceedings of the National Academy of Sciences of the United States

October 22, 2024 vol. 121 no. 43 https://www.pnas.org/toc/pnas/121/43 Opinion October 16, 2024Front Matter

Science offers the best way of knowing—as long as we don't confuse what "is" with what "ought to be"

W. Ford Doolittle

PNAS Nexus

Volume 3, Issue 9, September 2024 https://academic.oup.com/pnasnexus/issue/3/9 [Reviewed earlier]

Prehospital & Disaster Medicine

Volume 39 - Issue 3 - June 2024 https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue [New issue; No digest content identified]

Preventive Medicine

Volume 187 October 2024 https://www.sciencedirect.com/journal/preventive-medicine/vol/187/suppl/C [Reviewed earlier]

Proceedings of the Royal Society B

October 2024 Volume 291 Issue 2032 https://royalsocietypublishing.org/toc/rspb/current [Reviewed earlier]

Public Health

Volume 235 Pages 1-218 (October 2024) https://www.sciencedirect.com/journal/public-health/vol/235/suppl/C [Reviewed earlier]

Public Health Ethics

Volume 17, Issue 1-2, April/July 2024 http://phe.oxfordjournals.org/content/current [Reviewed earlier]

Public Health Genomics

2024, Vol. 27, No. 1 https://karger.com/phg/issue/27/1 [Reviewed earlier]

Public Health Reports

Volume 139 Issue 5, September/October 2024 https://journals.sagepub.com/toc/phrg/139/5 [Reviewed earlier]

Qualitative Health Research

Volume 34 Issue 11, September 2024 https://journals.sagepub.com/toc/QHR/current [Reviewed earlier]

Research Ethics

Volume 20 Issue 4, October 2024 http://journals.sagepub.com/toc/reab/current [Reviewed earlier]

Reproductive Health

http://www.reproductive-health-journal.com/content [Accessed 26 Oct 2024] [No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)

https://www.paho.org/journal/en Latest Articles [No new digest content identified]

Risk Analysis

Volume 44, Issue 10 Pages: 2313-2515 October 2024 https://onlinelibrary.wiley.com/toc/15396924/current [New issue; No digest content identified]

Risk Management and Healthcare Policy

https://www.dovepress.com/risk-management-and-healthcare-policy-archive56 [Accessed 26 Oct 2024] [No new digest content identified]

Science

Volume 386| Issue 6720| 25 Oct 2024 https://www.science.org/toc/science/current [New issue; No digest content identified]

Science and Engineering Ethics

Volume 30, Issue 5 October 2024 https://link.springer.com/journal/11948/volumes -and-issues/30-5 [Reviewed earlier]

Science Translational Medicine

Volume 16| Issue 770| 23 Oct 2024 https://www.science.org/toc/stm/current

From blood to mucosa

BY Jinyi Tang, Jie Sun

23 Oct 2024

Current COVID-19 vaccines induce suboptimal respiratory mucosal immunity even after mRNA boosters (Declercq et al. and Lasrado et al., this issue).

Research Articles

Repeated COVID-19 mRNA-based vaccination contributes to SARS-CoV-2 neutralizing antibody responses in the mucosa

BY Jozefien Declercq, et al.

23 Oct 2024

mRNA booster vaccines for SARS-CoV-2 induce circulating virus neutralizing antibodies that may enter the respiratory mucosa

SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity

BY Ninaad Lasrado, et al.

23 Oct 2024

COVID-19 mRNA booster vaccines induce limited mucosal immunity.

Scientific Reports

https://www.nature.com/srep/articles?type=article [Accessed 26 Oct 2024] [No new digest content identified]

Social Science & Medicine

Volume 358 October 2024 https://www.sciencedirect.com/journal/social-science-and-medicine/vol/358/suppl/C [Reviewed earlier]

Systematic Reviews

https://systematicreviewsjournal.biomedcentral.com/articles [Accessed 26 Oct 2024] [No new digest content identified]

Theoretical Medicine and Bioethics

Volume 45, Issue 5 October 2024 https://link.springer.com/journal/11017/volumes-and-issues/45-5 [Reviewed earlier]

Travel Medicine and Infectious Diseases

Volume 61 September–October 2024

https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/61/suppl/C [Reviewed earlier]

Tropical Medicine & International Health

Volume 29, Issue 10 Pages: i-iv, 849-921 October 2024 https://onlinelibrary.wiley.com/toc/13653156/current [Reviewed earlier]

Vaccine

Volume 42, Issue 25 14 November 2024 https://www.sciencedirect.com/journal/vaccine/vol/42/issue/25 [Reviewed earlier]

Vaccines

https://www.mdpi.com/journal/vaccines [Accessed 26 Oct 2024] Open Access Article

The Health and Economic Benefits of United States Investments in Measles and Rubella Control and Elimination

by Kimberly M. Thompson

Vaccines 2024, 12(11), 1210; https://doi.org/10.3390/vaccines12111210 - 25 Oct 2024 Abstract

Background: Prior to measles vaccine introduction in 1963, measles virus caused hundreds of thousands of annual reported cases, which led to substantial US morbidity, mortality, and costs. Similarly, congenital rubella syndrome (CRS) led to highly visible and tragic lifelong disability for thousands of [...]

Value in Health

October 2024 Volume 27 Issue 10 p1311-1468 https://www.valueinhealthjournal.com/current [Reviewed earlier]

World Development

Volume 182 October 2024 https://www.sciencedirect.com/journal/world-development/vol/182/suppl/C [Reviewed earlier]

::::::

Contents [click to move among sections]

- :: Milestones, Perspectives
- :: WHO
- :: Organization Announcements
- :: Journal Watch

:: <u>Pre-Print Servers</u>

::::::

Pre-Print Servers

arxiv

https://arxiv.org/

[Accessed 26 Oct 2024]

[Filter: Genomics; Neurons and Cognition; Populations and Evolution; Other Quantitative Biology;

General Economics] arXiv:2410.13923

Mathematical modelling to inform outbreak response vaccination

Manjari Shankar (1), Anna-Maria Hartner (1 and 2), Callum R. K. Arnold (3), Ezra Gayawan (4), Hyolim Kang (5), Jong-Hoon Kim (6), Gemma Nedjati Gilani (1), Anne Cori (1), Han Fu (5), Mark Jit (5 and 11), Rudzani Muloiwa (7), Allison Portnoy (8 and 9), Caroline Trotter (1 and 10), Katy A. M. Gaythorpe Comments: 19 pages including references and abstract, 1 figure

Subjects: Populations and Evolution (q-bio.PE)

Mathematical models are established tools to assist in outbreak response. They help characterise complex patterns in disease spread, simulate control options to assist public health authorities in decision-making, and longer-term operational and financial planning. In the context of vaccine-preventable diseases (VPDs), vaccines are one of the most-cost effective outbreak response interventions, with the potential to avert significant morbidity and mortality through timely delivery. Models can contribute to the design of vaccine response by investigating the importance of timeliness, identifying high-risk areas, prioritising the use of limited vaccine supply, highlighting surveillance gaps and reporting, and determining the short- and long-term benefits. In this review, we examine how models have been used to inform vaccine response for 10 VPDs, and provide additional insights into the challenges of outbreak response modelling, such as data gaps, key vaccine-specific considerations, and communication between modellers and stakeholders. We illustrate that while models are key to policy-oriented outbreak vaccine response, they can only be as good as the surveillance data that inform them.

Gates Open Research

https://gatesopenresearch.org/browse/articles

[Accessed 26 Oct 2024]

Study Protocol metrics Revised

<u>Vaccine decision-making among pregnant women: a protocol for a cross-sectional mixed-method study in Brazil, Ghana, Kenya and Pakistan</u>

[version 2; peer review: 1 approved, 1 approved with reservations, 1 not approved]
Jessica L Schue, Prachi Singh, Berhaun Fesshaye, Emily S Miller, Shanelle Quinn, Ruth A Karron,
Renato T Souza, Maria Laura Costa, Jose Guilherme Cecatti, Kwasi Torpey, Caroline Dinam Badzi,
Emefa Modey, Chris Guure, Ferdinand Okwaro, Marleen Temmerman, Saleem Jessani, Sarah Saleem,
Muhammad Asim, Sidrah Nausheen, Haleema Yasmeen, Grace Belayneh, Vanessa Brizuela, Sami
Gottlieb, Rupali J Limaye

Peer Reviewers Edina Amponsah-Dacosta and Imen Ayouni Ep Labidi; Lucía Abascal Miguel; Thiago Cerqueira-Silva

- Funder
- UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), a cosponsored programme executed by the World Health Organization (WHO).

medRxiv

https://www.medrxiv.org/content/about-medrxiv

[Accessed 26 Oct 2024] [Filter: All articles]

<u>Public reporting guidelines for outbreak data: Enabling accountability for effective</u> outbreak response by developing standards for transparency and uniformity

Vanessa Grégoire, Alex W Zhu, Catherine M Brown, John S Brownstein, Denise Cardo, Fergus Cumming, Richard Danila, Christl A Donnelly, Jeffrey S Duchin, Mary-Margaret A Fill, Christophe Fraser, Katie Fullerton, Sebastian Funk, Dylan George, Susan Hopkins, Moritz U. G. Kraemer, Marcelle Layton, Justin Lessler, Ruth Lynfield, James M McCaw, Tristan D McPherson, Zack Moore, Oliver Morgan, Steven Riley, Roni Rosenfeld, Erika Samoff, William Schaffner, Julie Shaffner, Roberta Sturm, Dawn Terashita, Henry Walke, Raynard E Washington, Caitlin M Rivers

medRxiv 2024.10.24.24315886; doi: https://doi.org/10.1101/2024.10.24.24315886

Currently, there are few standards for what essential information about an infectious disease outbreak should be reported to the public and when. The content and timeliness of public reporting (e.g. situation reports) is at the discretion of the jurisdiction overseeing the outbreak response, resulting in a substantial heterogeneity in available information. To address this problem, we undertook a consensus process to develop recommendations for what epidemiological information public health authorities should report to the public during an outbreak, including the administrative level and frequency of reporting.

Extreme weather events and dengue in Southeast Asia: a regionally-representative analysis of 291 locations from 1998 to 2021

Sophearen Ith, Xerxes Seposo, Vitou Phy, Kraichat Tantrakarnapa, Geminn Louis C. Apostol, Pandji Wibawa Dhewantara, Rozita Hod, Mohd Rohaizat Hassan, Hidayatulfathi Othman, Mazrura Sahani, Jue Tao Lim, Ha Hong Nhung, Nguyen Hai Tuan, Ngu Duy Nghia, Taichiro Takemura, Inthavong Nouhak, Paul Lester Carlos Chua, Alex R Cook, Felipe J Colón-González, Masahiro Hashizume medRxiv 2024.10.24.24316055; doi: https://doi.org/10.1101/2024.10.24.24316055

The global burden of chikungunya virus and the potential benefit of vaccines

Gabriel Ribeiro dos Santos, Fariha Jawed, Christinah Mukandavire, Arminder Deol, Danny Scarponi, Leonard Mboera, Eric Seruyange, Mahieu J. P. Poirier, Samuel Bosomprah, Augustine O. Udeze, Koussay Dellagi, Nathanaël Hozé, Jaffu Chilongola, Gheyath K. Nasrallah, Elmar Saathoff, Simon Cauchemez, Henrik Salje

medRxiv 2024.10.24.24315872; doi: https://doi.org/10.1101/2024.10.24.24315872

<u>"Evaluating the Impact of Artificial Intelligence on Vaccine Development: Lessons Learned</u> from the COVID-19 Pandemic"

Arshia Farmahini Farahani, Nika Kasraei medRxiv 2024.10.23.24315991; doi: https://doi.org/10.1101/2024.10.23.24315991

<u>Fever. A retrospective and prospective evaluation study in over 180 locations around the</u> world

Skyler Wu, Austin Meyer, Leonardo Clemente, Lucas M. Stolerman, Fred Lu, Atreyee Majumder, Rudi Verbeeck, Serge Masyn, Mauricio Santillana

medRxiv 2024.10.22.24315925; doi: https://doi.org/10.1101/2024.10.22.24315925

<u>Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada</u>

Raphael Ximenes, Alison E. Simmons, Gebremedhin B. Gebretekle, Austin Nam, Eva Wong, Marina I. Salvadori, Alyssa R. Golden, Beate Sander, Kyla J. Hildebrand, Matthew Tunis, Ashleigh R. Tuite medRxiv 2024.10.21.24315770; doi: https://doi.org/10.1101/2024.10.21.24315770

Exploring social determinants of childhood vaccination based on the National Immunization Surveys Data

Felix M. Pabon-Rodriguez

medRxiv 2024.10.18.24315767; doi: https://doi.org/10.1101/2024.10.18.24315767

OSF Pre-prints

https://osf.io/preprints/discover?provider=OSF&subject=bepress%7 CLife%20Sciences
[Provider Filter: OSF Pre-prints Subject filters: Medicine and Health Sciences Format Filter: Pre[No new digest content identified]

Wellcome Open Research

https://wellcomeopenresearch.org/browse/articles

[Accessed 26 Oct 2024]

Systematic Review Open Access

REVISED- Community-Based Health Information Systems in Africa: A Scoping Review of Data Generation, Utilization, and Community Empowerment

[version 3; peer review: 4 approved]

Beatrice Kuvuna, et al.

Introduction

The community-based health information system (CBHIS) is a vital component of the community health system, as it assesses community-level healthcare service delivery and generates data for community health programme planning, monitoring, and evaluation. CBHIS promotes data-driven decision-making, by identifying priority interventions and programs, guiding resource allocation, and contributing to evidence-based policy development.

* * *

Think Tanks

Brookings [to 26 Oct 2024] http://www.brookings.edu/ Research No new digest content identified.

Center for Global Development [to 26 Oct 2024]

https://www.cgd ev.org/ All Research No new digest content identified.

Chatham House [to 26 Oct 2024] https://www.chathamhouse.org/

Selected Analysis, Comment, Events No new digest content identified.

Council on Foreign Relations [to 26 Oct 2024]

https://www.cfr.org/media/news-releases
New Releases [Selected]
No new digest content identified.

CSIS [to 26 Oct 2024]
https://www.csis.org/
Reports [Selected]
No new digest content identified.

Kaiser Family Foundation [to 26 Oct 2024] https://www.kff.org/search/?post_type=press-release

Newsroom

No new digest content identified.

McKinsey Global Institute [to 26 Oct 2024]

https://www.mckinsey.com/mgi/overview

Latest Research

The next big arenas of competition

October 23, 2024 -

Arenas are industries that transform the business landscape. Eighteen future arenas could reshape the global economy and generate \$29 trillion to \$48 trillion in revenues by 2040.

ODI [Overseas Development Institute] [to 26 Oct 2024]

https://odi.org/en/publications/

Publications [Selected]

The AfCFTA and the procurement of pharmaceuticals and vaccines

21 October 2024 Research report

Pew Research Center [to 26 Oct 2024]

https://www.pewresearch.org/ Latest Publications [Selected] No new digest content identified.

Rand [to 26 Oct 2024] https://www.rand.org/pubs.html Published Research [Selected] No new digest content identified.

Urban Institute [to 26 Oct 2024]

https://www.urban.org/publications

New Research Publications - Selected

World Economic Forum [to 26 Oct 2024]

https://agenda.weforum.org/press/
Media [Selected]
No new digest content identified.

::::::

Public Consultations/Call for Inputs/Call for Papers

Addendum to the Guideline on clinical development of vaccines to address clinical trials in immunocompromised individuals

EMA - Consultation dates: 19/07/2024 to 31/10/2024

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (<u>CVEP</u>) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

Copyright GE2P2 Global Foundation 2024. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

:::::::

CVEP is a program of the <u>GE2P2 Global Foundation</u> whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the <u>Bill & Melinda Gates Foundation</u>; the <u>Bill & Melinda Gates Medical Research Institute</u>, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.